The clinical impact of pharmacogenetics on the treatment of epilepsy
Version of Record online: 9 JUL 2008
Wiley Periodicals, Inc. © 2008 International League Against Epilepsy
Volume 50, Issue 1, pages 1–23, January 2009
How to Cite
Löscher, W., Klotz, U., Zimprich, F. and Schmidt, D. (2009), The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, 50: 1–23. doi: 10.1111/j.1528-1167.2008.01716.x
- Issue online: 5 JAN 2009
- Version of Record online: 9 JUL 2008
- Accepted May 6, 2008; Early View publication July 9, 2008.
- Antiepileptic drugs;
- Gene variation;
- Single nucleotide polymorphism;
- Drug resistance;
Drug treatment of epilepsy is characterized by unpredictability of efficacy, adverse drug reactions, and optimal doses in individual patients, which, at least in part, is a consequence of genetic variation. Since genetic variability in drug metabolism was reported to affect the treatment with phenytoin more than 25 years ago, the ultimate goal of pharmacogenetics is to use the genetic makeup of an individual to predict drug response and efficacy, as well as potential adverse drug events. However, determining the practical relevance of pharmacogenetic variants remains difficult, in part because of problems with study design and replication. This article reviews the published work with particular emphasis on pharmacogenetic alterations that may affect efficacy, tolerability, and safety of antiepileptic drugs (AEDs), including variation in genes encoding drug target (SCN1A), drug transport (ABCB1), drug metabolizing (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins. Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B*1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Although genetic testing raises ethical and social issues, a better understanding of the genetic influences on epilepsy outcome is key to developing the much needed new therapeutic strategies for individuals with epilepsy.